AstraZeneca's Imfinzi Cancer-Drug Trial Misses the Mark
November 16 2018 - 2:45AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) reported negative results from a phase
3 trial of its cancer drug Imfinzi on Friday.
The company said the Mystic trial, which examined Imfinzi as a
treatment for previously untreated patients with metastatic
nonsmall-cell lung cancer, didn't meet its primary objective.
Patients being treated with either Imfinzi alone, or the drug plus
tremelimumab, didn't demonstrate a statistically significant
improvement in overall survival when compared with platinum-based
chemotherapy, it said.
Imfinzi is approved as a treatment for inoperable stage 3
nonsmall-cell lung cancer in more than 40 countries. It's currently
being tested in a number of phase 3 trials as a treatment for stage
4 nonsmall-cell lung cancer, the Anglo-Swedish pharmaceutical
company said.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 16, 2018 02:30 ET (07:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024